After achieving billions in sales, the World Health Organization is no longer recommending two antibody treatments for the Corona virus, on the grounds that they are no longer effective for treating the virus, due to the Omicron strain and its sub-mutants, according to the Archyde.com website.
The FDA has withdrawn Regeneron from the market despite its prior approval
The two treatments, designed to work by binding to the skeletal protein of the Corona virus, to neutralize the ability of the virus to infect cells, are among the first drugs developed early in the Corona pandemic, the agency said..
The two treatments, designed to work by binding to the virus’s skeletal protein to neutralize its ability to infect cells, were among the first drugs developed early in the pandemic..
Increasing evidence from laboratory tests indicates that the efficacy of the treatments “sotrovimab” and “cacerifimab-imdivimab”, is limited in the face of the latest mutations of the virus, and as a result, they have also been excluded by the health regulator in the United States..
Experts of the World Health Organization said that they were strongly advised not to use them to treat people infected with the Corona virus, as part of a set of new recommendations published by the British Medical Journal.
The agency confirmed that the virus has evolved since then. The World Health Organization experts said that they strongly advised not to use them to treat people infected with the virus coronain retraction of conditional recommendations for their use.
Billions of sales
The agency stated that the US Food and Drug Administration FDA Sotrofimab, produced by GlaxoSmith and its partner Fair Biotechnology, has been withdrawn from the local market, and the drug has generated billions in sales and became one of the best-selling drugs produced by British companies last year..
The antibody combination cacerifimab-imdivimab, produced by Regeneron and its partner Roche, also generated billions in sales and was one of the best-selling US drugs last year.
No efficacy in front of Omicron
The US Food and Drug Administration revised its position on the treatment in January and limited its use to a smaller group of patients, citing poor potency against the Omicron variant, though the European Medicines Regulatory Authority still recommends both treatments.